BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 35318962)

  • 1. Personalised medicines for familial hypercalcemia and hyperparathyroidism.
    Josephs TM; Zhang F; Dinh LV; Keller AN; Conigrave AD; Capuano B; Gregory KJ; Leach K
    J Mol Endocrinol; 2022 May; 69(1):243-257. PubMed ID: 35318962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcium signaling regulates trafficking of familial hypocalciuric hypercalcemia (FHH) mutants of the calcium sensing receptor.
    Grant MP; Stepanchick A; Breitwieser GE
    Mol Endocrinol; 2012 Dec; 26(12):2081-91. PubMed ID: 23077345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cinacalcet Reverses Short QT Interval in Familial Hypocalciuric Hypercalcemia Type 1.
    Cuny T; Romanet P; Goldsworthy M; Guérin C; Wilkin M; Roche P; Sebag F; van Summeren LE; Stevenson M; Howles SA; Deharo JC; Thakker RV; Taïeb D
    J Clin Endocrinol Metab; 2024 Jan; 109(2):549-556. PubMed ID: 37602721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cinacalcet therapy in a child with novel homozygous CASR p.Glu353Lys mutation causing familial hypocalciuric hypercalcemia type 1: case report and review of the literature.
    Koca SB
    Turk J Pediatr; 2023; 65(5):853-861. PubMed ID: 37853976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cinacalcet Rectifies Hypercalcemia in a Patient With Familial Hypocalciuric Hypercalcemia Type 2 (FHH2) Caused by a Germline Loss-of-Function Gα
    Gorvin CM; Hannan FM; Cranston T; Valta H; Makitie O; Schalin-Jantti C; Thakker RV
    J Bone Miner Res; 2018 Jan; 33(1):32-41. PubMed ID: 28833550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allosteric Modulation of the Calcium-sensing Receptor Rectifies Signaling Abnormalities Associated with G-protein α-11 Mutations Causing Hypercalcemic and Hypocalcemic Disorders.
    Babinsky VN; Hannan FM; Gorvin CM; Howles SA; Nesbit MA; Rust N; Hanyaloglu AC; Hu J; Spiegel AM; Thakker RV
    J Biol Chem; 2016 May; 291(20):10876-85. PubMed ID: 26994139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Markedly reduced activity of mutant calcium-sensing receptor with an inserted Alu element from a kindred with familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism.
    Bai M; Janicic N; Trivedi S; Quinn SJ; Cole DE; Brown EM; Hendy GN
    J Clin Invest; 1997 Apr; 99(8):1917-25. PubMed ID: 9109436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced affinity of calcium sensing-receptor heterodimers and reduced mutant homodimer trafficking combine to impair function in a model of familial hypocalciuric hypercalcemia type 1.
    Wang X; Lundblad J; Smith SM
    PLoS One; 2022; 17(7):e0266993. PubMed ID: 35857775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subtotal Parathyroidectomy Successfully Controls Calcium Levels of Patients with Neonatal Severe Hyperparathyroidism Carrying a Novel CASR Mutation.
    Wejaphikul K; Dejkhamron P; Khorana J; Watcharachan K; Intachai W; Olsen B; Tongsima S; Ketudat Cairns JR; Ngamphiw C; Kantaputra P
    Horm Res Paediatr; 2023; 96(4):432-438. PubMed ID: 36626889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of clinically relevant mutations on the pharmacoregulation and signaling bias of the calcium-sensing receptor by positive and negative allosteric modulators.
    Leach K; Wen A; Cook AE; Sexton PM; Conigrave AD; Christopoulos A
    Endocrinology; 2013 Mar; 154(3):1105-16. PubMed ID: 23372019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel homozygous inactivating mutation of the calcium-sensing receptor gene in neonatal severe hyperparathyroidism responding to cinacalcet therapy: A case report and literature review.
    Sun X; Huang L; Wu J; Tao Y; Yang F
    Medicine (Baltimore); 2018 Nov; 97(45):e13128. PubMed ID: 30407334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cinacalcet as a First-Line Treatment in Neonatal Severe Hyperparathyroidism Secondary to Calcium Sensing Receptor (CaSR) Mutation.
    Gulcan-Kersin S; Kirkgoz T; Eltan M; Rzayev T; Ata P; Bilgen H; Ozek E; Bereket A; Turan S
    Horm Res Paediatr; 2020; 93(5):313-321. PubMed ID: 33147586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neonatal hypercalcemia due to a homozygous mutation in the calcium-sensing receptor: failure of cinacalcet.
    García Soblechero E; Ferrer Castillo MT; Jiménez Crespo B; Domínguez Quintero ML; González Fuentes C
    Neonatology; 2013; 104(2):104-8. PubMed ID: 23817301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GENETICS IN ENDOCRINOLOGY: Gain and loss of function mutations of the calcium-sensing receptor and associated proteins: current treatment concepts.
    Mayr B; Schnabel D; Dörr HG; Schöfl C
    Eur J Endocrinol; 2016 May; 174(5):R189-208. PubMed ID: 26646938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired cotranslational processing of the calcium-sensing receptor due to signal peptide missense mutations in familial hypocalciuric hypercalcemia.
    Pidasheva S; Canaff L; Simonds WF; Marx SJ; Hendy GN
    Hum Mol Genet; 2005 Jun; 14(12):1679-90. PubMed ID: 15879434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and characterization of a novel CASR mutation causing familial hypocalciuric hypercalcemia.
    Lin CM; Ding YX; Huang SM; Chen YC; Lee HJ; Sung CC; Lin SH
    Front Endocrinol (Lausanne); 2024; 15():1291160. PubMed ID: 38487341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cinacalcet corrects biased allosteric modulation of CaSR by AHH autoantibody.
    Makita N; Ando T; Sato J; Manaka K; Mitani K; Kikuchi Y; Niwa T; Ootaki M; Takeba Y; Matsumoto N; Kawakami A; Ogawa T; Nangaku M; Iiri T
    JCI Insight; 2019 Apr; 4(8):. PubMed ID: 30996138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and functional characterization of loss-of-function mutations of the calcium-sensing receptor in four Italian kindreds with familial hypocalciuric hypercalcemia.
    Cetani F; Lemmi M; Cervia D; Borsari S; Cianferotti L; Pardi E; Ambrogini E; Banti C; Brown EM; Bagnoli P; Pinchera A; Marcocci C
    Eur J Endocrinol; 2009 Mar; 160(3):481-9. PubMed ID: 19073830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A homozygous inactivating calcium-sensing receptor mutation, Pro339Thr, is associated with isolated primary hyperparathyroidism: correlation between location of mutations and severity of hypercalcaemia.
    Hannan FM; Nesbit MA; Christie PT; Lissens W; Van der Schueren B; Bex M; Bouillon R; Thakker RV
    Clin Endocrinol (Oxf); 2010 Dec; 73(6):715-22. PubMed ID: 20846291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium-sensing-related gene mutations in hypercalcaemic hypocalciuric patients as differential diagnosis from primary hyperparathyroidism: detection of two novel inactivating mutations in an Italian population.
    Stratta P; Merlotti G; Musetti C; Quaglia M; Pagani A; Izzo C; Radin E; Airoldi A; Baorda F; Palladino T; Leone MP; Guarnieri V
    Nephrol Dial Transplant; 2014 Oct; 29(10):1902-9. PubMed ID: 25104082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.